Back to News
Market Impact: 0.3
Zevra Therapeutics Q3 Earnings Call Highlights
Source: marketbeat.com
Corporate EarningsHealthcare & BiotechCompany Fundamentals
Zevra Therapeutics reported third-quarter 2026 net revenue of $37.8 million, up 45% from $26.1 million a year earlier. Growth was driven primarily by U.S. sales of MIPLYFFA for Niemann-Pick disease type C.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.35
Ticker Sentiment
ZVRA0.55
More News
- Binance co-CEO Richard Teng says hackers used fake job interviews, AI tool to steal $6.3 billion in crypto 108511116
- AMD stock jumps 7% on earnings as data center revenue nearly doubles
- Marvell Technology could plunge on latest multibillion-dollar acquisition
- Disney Plans Thousands of Layoffs Companywide
- AMD rides data center riches to ‘largest and most profitable’ quarter in history
- ‘Lawyer up’: Democrats take the House, and warn Trump’s family businesses are first in line for subpoenas